- 10% beat on EBITDA vs cons - Strong growth in Technology, but continued weakness in Genetics - Est...
Redeye considers Arise’s Q2 2024 report to be solid, where the reported EBITDA was completely in lin...
Redeye comments on Doro´s second quarter of the year.
- EBIT SEK 131m (-11% vs. ABGSCe, -4% vs. FactSet cons) - We expect consensus EBIT to come down by 2...
Redeye updates its estimates and valuation following Serstech's Q1 2024 report.
- Q2 sales impacted by lower Public DK deliveries – again - We cut '24e-'26e EBIT by 12-5% on lower ...
- Rising freight rates dilute the gross margin - '24e-'26e EBITA down 5-1% - '24e-'25e lease adj.
- Order intake growth driven by sports & outdoor clients - We raise '24e-'26e sales by 2-1% and EBIT...
Redeye updates its estimates for Ependion following the Q2 2024 report, which showed stronger sales ...
Aixia nästan tredubblar nettoomsättningen i det andra kvartalet och fortsätter att skörda framgångar...
Redeye provides an initial comment on the Q2 2024 report from Serstech.
Redeye comments on the latest readout from the trial of tasquinimod in multiple myeloma.
Redeye will likely increase its Base Case and forecasts following a strong Q2 report, with solid imp...
SRV reports its Q2 results on Thursday 18th of July.
- Q2: 8% organic sales growth, but adj. EBITA down 6% y-o-y - Platform & Sportsbook signings have be...
- Q2 in line with ABGSCe but softer outlook for Q3 - We cut adj.
Redeye has updated its estimates for Carasent following the Q2 2024 report, which was quite undramat...
Redeye provides a more in-depth review of Episurf Medical’s Q2 report.
XVIVO delivered an organic growth surprise at 32% (CER, 32% in Q1) during Q2 a quarter, with a subst...
Ahead of the Fiskars Q2, due on 18 July, we maintain our estimates intact.